Stem cell transplantation for DADA2Nature.comHaematopoietic stem cell transplantation (HSCT) was an effective and definitive treatment in 14 patients with deficiency of adenosine deaminase 2 (DADA2), a monogenic autoinflammatory vasculopathy. All patie… Continue reading
Stem cell transplantation for DADA2Nature.comHaematopoietic stem cell transplantation (HSCT) was an effective and definitive treatment in 14 patients with deficiency of adenosine deaminase 2 (DADA2), a monogenic autoinflammatory vasculopathy. All patie… Continue reading
MassiveNew CAR-T cell therapy offers effective option for certain blood cancer patientsNews-Medical.netThe first cancers to be treated with CAR-T cell therapy include certain types of large B-cell lymphomas in adults and acute lymphoblastic leukemia (… Continue reading
|
Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
Nasdaq SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing … |
|
Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
Nasdaq SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing … |
|
Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
Nasdaq SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing … |
|
Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
Nasdaq SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing … |
|
Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
Nasdaq SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) — Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer, will be giving an oral presentation on Prima’s ongoing … |